5 Biotech Stocks Poised for Breakouts
Transcept Pharmaceuticals
Another biotech stock that's approaching a near-term breakout trade is Transcept Pharmaceuticals (TSPT), a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. This stock is off to a slow start in 2012, with shares off by around 16% so far.
If you look at the chart for Transcept Pharmaceuticals, you'll notice that this stock has been hammered during the last four months, with shares plunging from a high of $12.99 to a recent low of $5.81 a share. During that plunge, shares of TSPT had been consistently making lower highs and lower lows, which is bearish technical price action.
That said, shares of TSPT now look to have bottomed since the stock has found buying interest at around $5.81 to $5.95 during the last two months. That possible bottom has now put a major breakout into focus if TSPT can manage to clear some near-term overhead resistance levels.
>>5 Huge Stocks Ready to Slingshot Higher Market players should now look for long-biased trades in TSPT if it can manage to trigger a near-term breakout trade above some overhead resistance levels at $6.70 to $6.73 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 245,600 shares. If we get that action soon, then TSPT could easily re-test and possibly take out some more resistance levels at $7.45 and its 200-day moving average of $7.97 a share. One could buy TSPT off any weakness and simply use a stop close to some near-term support at $6.16 a share. You could also just get long off strength once TSPT clears $6.70 to $6.73 with heavy volume. If you buy off strength, then I would use a stop near its 50-day moving average of $6.51, or even down towards $6.16 if you want to give it more room.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV